Study sheds light on the biology of progressive form of multiple sclerosis, suggests a new potential path for treatment

February 8, 2017, Brigham and Women's Hospital

A research team led by scientists from Brigham and Women's Hospital has revealed how an FDA-approved drug works in the central nervous system in mice to suppress chronic inflammation. The drug, known as FTY720 (or Fingolimod) interferes with signals sent through sphingosine-1-phosphate receptors, and appears to reduce the pathogenic activities of astrocytes. The findings suggest the treatment may hold promise for a progressive and difficult-to-treat form of multiple sclerosis (MS) known as secondary progressive MS (SPMS).

"One of the most important unmet clinical needs in MS is to design therapeutic approaches for the progressive phase of the disease," said senior author Francisco Quintana, PhD, a researcher in the Ann Romney Center for Neurologic Diseases at BWH. "And a key unanswered question related to that is, what are the biological processes that drive disease pathogenesis at this stage?"

MS is a that affects the central nervous system. It frequently begins with a relapsing-remitting course that often gives way to second phase, SPMS, which is characterized by severe and irreversible neurological decline. Unfortunately, there are few therapies that target this form of MS. Notably, treatments for the relapsing-remitting phase of the disease are ineffective against SPMS.

The current study, published in PNAS and led by Quintana and his colleagues, sheds new light on the role of sphingosine-1-phosphate, a type of lipid, and its receptors in SPMS. The researchers found that blockage of these signals with FTY720 had important effects on astrocytes in both mice and humans, decreasing their pro-inflammatory and neurotoxic properties while also increasing the cells' anti-inflammatory capabilities.

Although the findings are noteworthy, the neuroprotective effects Quintana and his colleagues observe are not as strong as those they have recorded in previous studies of other drugs. Nevertheless, the results suggest FTY720 may help mitigate some aspects of SPMS in humans. A clinical trial of a highly related drug, led by Novartis, is now underway and encouraging preliminary results have been recently released, Quintana said.

Explore further: Imaging against multiple sclerosis: Iodinated radiotracer candidate for PET and SPECT imaging

More information: Veit Rothhammer et al, Sphingosine 1-phosphate receptor modulation suppresses pathogenic astrocyte activation and chronic progressive CNS inflammation, Proceedings of the National Academy of Sciences (2017). DOI: 10.1073/pnas.1615413114

Related Stories

Imaging against multiple sclerosis: Iodinated radiotracer candidate for PET and SPECT imaging

February 4, 2011
(PhysOrg.com) -- A first-line treatment for relapsing forms of multiple sclerosis (MS) was approved in September 2010 by the US Food and Drug Administration: FTY720 (fingolimod, Gilenya), which acts as a sphingosine 1-phosphate ...

Stem cell transplants may induce long-term remission of multiple sclerosis

February 1, 2017
New clinical trial results provide evidence that high-dose immunosuppressive therapy followed by transplantation of a person's own blood-forming stem cells can induce sustained remission of relapsing-remitting multiple sclerosis ...

Receptor variation influences fingolimod efficacy in mouse multiple sclerosis models

June 16, 2016
Multiple sclerosis (MS) is an autoimmune disorder that results in demyelination of neurons. The FDA-approved drug fingolimod (Gilenya, FTY-720) modulates signaling by the bioactive lipid sphingosine-1-phosphate (S1P), which ...

Exploring the gut-brain connection for insights into multiple sclerosis

May 9, 2016
New research by investigators at Brigham and Women's Hospital (BWH) suggests that bacteria living in the gut may remotely influence the activity of cells in the brain that are involved in controlling inflammation and neurodegeneration. ...

Basic research shows that drug used to treat multiple sclerosis may have beneficial effects on memory

May 28, 2014
(Medical Xpress)—Virginia Commonwealth UniversitySchool of Medicine researchers have uncovered a new mechanism of action of fingolimod, a drug widely used to treat multiple sclerosis: elimination of adverse or traumatic ...

Primary progressive and relapsing remitting multiple sclerosis treated with ocrelizumab

October 21, 2015
Three phase three clinical studies using the drug ocrelizumab to treat patients with multiple sclerosis (MS) have yielded positive results for treating two forms of the disease and the first ever positive results for a treatment ...

Recommended for you

Use of electrical brain stimulation to foster creativity has sweeping implications

September 18, 2018
What is creativity, and can it be enhanced—safely—in a person who needs a boost of imagination? Georgetown experts debate the growing use of electrical devices that stimulate brain tissue, and conclude there is potential ...

Engineers decode conversations in brain's motor cortex

September 18, 2018
How does your brain talk with your arm? The body doesn't use English, or any other spoken language. Biomedical engineers are developing methods for decoding the conversation, by analyzing electrical patterns in the motor ...

Team identifies brain's lymphatic vessels as new avenue to treat multiple sclerosis

September 17, 2018
Lymphatic vessels that clean the brain of harmful material play a crucial role in the development and progression of multiple sclerosis, new research from the University of Virginia School of Medicine suggests. The vessels ...

Circuit found for brain's statistical inference about motion

September 17, 2018
As the eye tracks a bird flying past, the muscles that pan the eyeballs to keep the target in focus set their pace not only on the speed they see, but also on a reasonable estimate of the speed they expect from having watched ...

Mouse study reveals that activity, not rest, speeds recovery after brain injury

September 17, 2018
When recovering from a brain injury, getting back in the swing of things may be more effective than a prolonged period of rest, according to a new Columbia study in mice. These findings offer a compelling example of the brain's ...

Fine-tuned sense of smell relies on timing

September 17, 2018
If you can tell the difference between a merlot and a cabernet franc just by smell, it's probably all in the timing.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.